"We are thrilled to welcome Dr. Sims to the SAB," says Dr. Mark Atkinson, Chairman of the Diamyd Medical Scientific Advisory Board. "Her groundbreaking research and clinical expertise will significantly enhance our efforts to advance precision medicine approaches for Type 1 Diabetes. Indeed, as we approach potential market introduction, Emily Sim's insights will be critical in shaping clinical awareness and positioning our therapy for maximum impact."

Dr. Sims is an Associate Professor of Pediatrics at Indiana University (IU) School of Medicine, a pediatric endocrinologist at Riley Hospital for Children, and a physician scientist at the IU Center for Diabetes and Metabolic Diseases and the Herman B Wells Center for Pediatric Research. Her work focuses on identifying risk factors that predispose individuals to Type 1-Diabetes and developing innovative treatments to prevent or slow disease progression.

 "I am honored to be part of Diamyd Medical's mission to bring precision medicine to Type 1 Diabetes", says Emily Sims. "As Diamyd Medical prepares to bring its precision medicine approach to patients, I look forward to contributing to its efforts to deliver pioneering treatments. The company's commitment to advancing innovative therapies aligns with my passion for improving risk prediction and developing treatments that can make a meaningful impact on patients' lives"

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd^® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Breakthrough Designation and Fast Track Designation by the U.S. FDA for the treatment of Stage 3 Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company's prospective European Phase IIb trial, where Diamyd^® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.